Global Hemodynamic Monitoring Systems Market 2021 (Includes Business Impact of COVID-19)

                                          
Report updated on 11th September, 2021: Global Hemodynamic Monitoring Systems Market 2021 (Includes Business Impact of COVID-19)
Global Hemodynamic Monitoring Systems Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2030 is a recent report generated by Trusted Business Insights. The global hemodynamic monitoring systems market report has been segmented on the basis of type, end user, and region.
Request Covid - 19 Impact
The global Hemodynamic Monitoring Systems market size was valued at USD$1858.75 million in 2020 and is projected to reach UDS$4155.20 million by 2030, and is anticipated to expand at a CAGR of 7.93% over the forecast period from 2020 to 2030.


Global Hemodynamic Monitoring Systems Market: Overview


A hemodynamic monitoring system is used in case where a patients cardiovascular health needs to be assessed, especially among those patients that have undergone a cardiac surgery. Hemodynamic monitoring systems are used in post-surgical rehabilitation of cardiac patients. Hemodynamic monitoring systems are used to examine the patients blood flow in detail and obtain various metrics about it, such as the amount of oxygen in the blood and blood pressure inside various parts of circulatory system.


Global Hemodynamic Monitoring Systems Market: Dynamics


Increasing government expenditure on healthcare sector in order to facilitate the healthcare services and increasing patient pool suffering from cardiovascular diseases are major factors expected to drive growth of the global market. In addition, technological innovations in minimally invasive procedures and non-invasive techniques used for hemodynamic monitoring is another factor expected to boost growth of the global market over the forecast period.

Moreover, increasing prevalence of lifestyle-related diseases, such as diabetes, hypertension, and obesity is resulting in heart-related disorders such as cardiac arrests, heart failures, and heart attacks which in turn expected to increasing demand for expected monitoring systems. This is another factor expected to support growth of the target market to certain extent.

Furthermore, increasing number of hospital surgeries, rising aging population, coupled with favorable reimbursement policies by the government of developed countries are some other factors expected to further support growth of the target market to certain extent.

However, adverse reactions such as bleeding, thrombosis, pulmonary capillary necrosis, sepsis, and hemorrhage, associated with invasive hemodynamic monitoring is a major factor expected to restrain growth of the global market over the forecast period.

Increasing investment by major players for technological advancements and R&D activities is expected to create new opportunities in terms of revenue for players operating in the target market over the forecast period. In addition, increasing expansion activates by major players through strategic partnership and agreements is expected to further support growth of the global market to certain extent.


Global Hemodynamic Monitoring Systems Market: Region Analysis


The market in North America is expected to dominate the global market and is expected to continue its dominance over the forecast period. The dominance can be attributed to well-developed healthcare infrastructure, favorable reimbursement policies, and presence of major players operating in the countries in this region. In addition, growing merger and acquisition activities among regional and international players is expected to further support growth of the target market in this region. The market in Asia Pacific is expected to witness faster growth, owing to rising disposable income and increasing patient pool suffering from diabetes, hypertension, and obesity. In addition, presence of prominent players operating in target market in emerging economies such as India and China in this region.


Below are the active patents related to Hemodynamic Monitoring Systems Market.


Patent Number: US10045701B2

Implantable hemodynamic monitor and methods for use therewith

Abstract

Provided herein are implantable systems that include an implantable photoplethysmography (PPG) sensor, which can be used to obtain an arterial PPG waveform. In an embodiment, a metric of a terminal portion of an arterial PPG waveform is determined, and a metric of an initial portion of the arterial PPG waveform is determined, and a surrogate of mean arterial pressure is determined based on the metric of the terminal portion and the metric of the initial portion. In another embodiment, a surrogate of diastolic pressure is determined based on a metric of a terminal portion of an arterial PPG waveform. In a further embodiment, a surrogate of cardiac afterload is determined based on a metric of a terminal portion of an arterial PPG waveform.

Application File Date: 2012-11-06

Application Granted Date: 2018-08-14

Current Assignee: Pacesetter Inc

Patent Number: US20030083582A1

Non-invasive method and device to monitor cardiac parameters

Abstract

A method of and a device for non-invasively measuring the hemodynamic state of a subject or a human patient involve steps and units of non-invasively measuring cardiac cycle period, electrical-mechanical interval, mean arterial pressure, and ejection interval and converting the measured electrical-mechanical interval, mean arterial pressure and ejection interval into the cardiac parameters such as Preload, Afterload and Contractility, which are the common cardiac parameters used by an anesthesiologist.

The converted hemodynamic state of a patient is displayed on a screen as a three-dimensional vector with each of its three coordinates respectively representing Preload, Afterload and Contractility. Therefore, a medical practitioner looks at the screen and quickly obtains the important and necessary information.

Application File Date: 2001-10-31

Application Granted Date: 2006-05-30

Inventor: Robert Hirsh

Patent Number: US7186219B2

Calibration of a doppler velocimeter for stroke volume determination

Abstract

Doppler Velocimetry is a widely used method for estimating stroke volume (SV). The accuracy and reliability of its measurement however, is dependant on
a) the correct assessment of the aortic valve cross-sectional area (CSA), and
b) the maximal systolic velocity integral (SVI).
The invention avoids the conventional assessment of aortic valve CSA by using a calibration method: a reference stroke volume SVREF is determined by a method different from Doppler velocimetry, e.g. by thoracic electrical bioimpedance (TEB), or thoracic electrical bioadmittance, measured via surface thorax electrodes (transthoracic approach) or via electrodes located directly on an esophageal catheter/probe (esophageal approach). In the latter case, if esophageal Doppler velocimetry is used, the same catheter can be used for the placement of the electrodes and for an ultrasound transducer. In the case of esophageal Doppler velocimetry, an additional benefit of the invention is that the Doppler catheter/probe does not need to be aimed precisely at the site of maximum flow amplitude, as long as a stable catheter/probe location is maintained within the esophagus.

Application File Date: 2002-10-10

Application Granted Date: 2007-03-06

Current Assignee: Osypka Medical GmbH

Global Hemodynamic Monitoring Systems Market Segmentation:

By Type:

  
Invasive Hemodynamic Monitoring Systems
  
Minimally Invasive Hemodynamic Monitoring Systems
  
Noninvasive Hemodynamic Monitoring Systems

By End User:

  
Hospitals
  
Clinics and Ambulatory Care Centers
  
Home Care Settings


Key Market Players included in the report:


  
Argon Medical Inc.
  
CareTaker Medical (US)
  
CHEETAH MEDICAL
  
CNSYSTEMS MEDIZINTECHNIK GMBH(Austria)
  
Deltex Medical Group plc.
  
dwards Lifesciences Corporation.
  
Edwards Lifesciences Corporation
  
GE Healthcare
  
Getinge AB
  
HEMO SAPIENS INC
  
ICU Medical Inc.
  
Koninklijke Philips NV
  
LiDCO Group Plc.
  
NI Medical (Israel)
  
NIHON KOHDEN CORPORATION
  
OSYPKA MEDICAL GMBH (Germany)
  
PULSION Medical Systems SE (Germany)
  
Schwarzer Cardiotek GmbH
  
Teleflex Incorporated.
  
Tensys Medical Inc.
  
Uscom (Australia)


Below are the key development related to Hemodynamic Monitoring Systems Market in 2020 and 2021.


June  2021: Abiomed Acquires preCARDIA, a Breakthrough Medical Device Company, to Improve Outcomes for Heart Failure Patients. Abiomed (NASDAQ: ABMD) has acquired preCARDIA, developer of a proprietary catheter and controller that will complement Abiomed’s product portfolio to expand options for patients with acute decompensated heart failure (ADHF). The preCARDIA system is uniquely designed to rapidly treat ADHF-related volume overload by effectively reducing cardiac filling pressures and promoting decongestion to improve overall cardiac and renal function.Annually, more than one million patients are admitted to hospitals in the United States with ADHF. Despite available pharmaceutical treatments, heart failure is the leading cause of hospitalization in patients older than 65 years of age. preCARDIA provides heart failure specialists a minimally invasive solution with the potential to improve patient outcomes and lower the cost of care by providing early intervention with this new technology. preCARDIA’s catheter-based system includes a proprietary superior vena cava (SVC) balloon that delivers programmed intermittent occlusion of the SVC. Potential benefits for patients include improved response to medical management of ADHF, reduced duration of hospital stay, reduced re-hospitalizations and improved quality of life. The system is based on an invention by Navin Kapur, MD, and Richard Karas, MD, PhD, at the Molecular Cardiology Research Institute at Tufts Medical Center in Boston. The design of the preCARDIA system allows for straightforward placement by physicians and hemodynamic monitoring by medical staff. The system has received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). Source

February  2021: Masimo Expands Suite of Advanced Measurements Through Acquisition of UK-Based LiDCO Group Plc. Leading Provider of Hemodynamic Monitoring Becomes Masimo Subsidiary Masimo (NASDAQ: MASI) announced that it has successfully completed the acquisition of the LiDCO Group Plc, a leading provider of advanced hemodynamic monitoring solutions (LiDCO). The Company completed the acquisition of 100% of LiDCO on February 2, 2021. Source

April 2020: Abiomed Expands Product Portfolio with Acquisition of Cardiopulmonary Support Technology (ECMO) to Improve Outcomes for Patients. Abiomed (NASDAQ: ABMD), maker of the Impella heart pump, has acquired Breethe, developer of a novel extracorporeal membrane oxygenation (ECMO) system that will complement and expand Abiomed’s product portfolio to more comprehensively serve the needs of patients whose lungs can no longer provide sufficient oxygenation, including patients suffering from cardiogenic shock or respiratory failure such as due to ARDS, H1N1, SARS, or COVID-19. ECMO has also been utilized as a primary method of oxygenation and hemodynamic support for pediatric patients. Source